Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Switching from Semaglutide to CagriSema in Type 2 Diabetes
NCT07817251Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 3, randomised trial of CagriSema in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by Novo Nordisk. Primary endpoint: Number of treatment emergent adverse events at 16 weeks. Started Sep 2026; status: recruiting.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07817251.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07817251.